SF3B1 and myelodysplastic syndrome: In myeloid malignancies such as MDS and AML, spliceosome mutations of SF3B1 or U2AF1 lead to formation of hypermorphic IRAK-4 isoforms (IRAK-4-L) which activate myddosomal signaling promoting cell survival.